Shots:

• Novartis to get an option to acquire IFM Due (a subsidiary of IFM Therapeutics) in exchange of funding for research & development of cGAS/STING program. Post exercising of option- IFM to receive $840M including up front and other contingent consideration
• IFM has two preclinical pipeline programs- first developing as oral STING antagonist having the ability for blocking excessive production of interferons & other pro-inflammatory cytokines- intended to enter into a clinical study in 2021 while the second as cGAS inhibitor blocking the pathway at the more upstream node
• The cGAS/STING pathway functions within the innate immune system to sense cytosolic DNA- triggering STING-dependent inflammatory response to treat chronic inflammatory and autoimmune diseases

Click here to­ read full press release/ article | Ref: IFM Therapeutics | Image: Twitter